NeuroPace price target raised to $14 from $9 at JPMorgan

JPMorgan raised the firm’s price target on NeuroPace (NPCE) to $14 from $9 and keeps an Overweight rating on the shares following a transfer of analysts. NeuroPace is an “undervalued company” with the “highly differentiated RNS asset” targeting a high unmet need in the multi-billion-dollar drug-resistant epilepsy market, the analyst tells investors in a research note. The firm says the company brings a clinically superior neuromodulation solution with minimal side effects to the large untapped drug-resistant epilepsy market.